3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
25
Recurrence
18
Multiple Myeloma
17
Lymphoma, Non-Hodgkin
14
Lymphoma, B-Cell
14
Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Ovarian Neoplasms
12
Hematologic Neoplasms
12
Pancreatic Neoplasms
10
Melanoma
10
Leukemia
9
Hodgkin Disease
9
Burkitt Lymphoma
9
Stomach Neoplasms
8
Myeloproliferative Disorders
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
7
Leukemia, Biphenotypic, Acute
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myelomonocytic, Chronic
6
Breast Neoplasms
6
Interventions
tislelizumab
1
fludarabine
1
Cyclophosphamide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Simpson-Golabi-Behmel syndrome
×
fludarabine
×
90 days
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled